Venus Remedies decline worries shareholders after massive yearly rise

Market pulse

From the investor's mind

India's major electric two-wheeler manufacturers are embarking on a massive production expansion that could reshape the green mobility landscape. Industry observer Aditya Kondawar points out that Ather, TVS, Bajaj, and Hero are all aiming to scale up their respective electric two-wheeler capacities to 80,000–90,000 units per month by next year. This coordinated expansion translates to an aggregate annual production capacity of nearly 40 lakh to 45 lakh units from just these four prominent players. While achieving these numbers will require a period of ramping up and operational stabilization, the aggressive targets underscore a major manufacturing push in the domestic electric vehicle space.

Word in the street

Venus Remedies Limited

Investors are closely discussing Venus Remedies Limited, a company with a market cap of about 1,646 crore whose stock has risen 183.67 percent over the past year. Despite this massive run up, a continuous price decline since early October has shareholders questioning if this is mere profit booking or something deeper. Some point to operational drags, noting that the consolidated net profit of 25.65 crore fell short of the standalone net profit of 28.96 crore due to a 5.84 crore net loss in its German subsidiary. Increased depreciation and amortization expenses also raised operational costs, leaving investors guessing where this slide will finally stop.

Yesterday's big moves

“The stock market is a device for transferring money from the impatient to the patient.”

Warren Buffett